U.S. markets closed
  • S&P 500

    +33.11 (+0.75%)
  • Dow 30

    +382.20 (+1.09%)
  • Nasdaq

    +73.91 (+0.50%)
  • Russell 2000

    -8.52 (-0.37%)
  • Crude Oil

    +1.35 (+1.66%)
  • Gold

    -29.80 (-1.66%)
  • Silver

    -0.13 (-0.54%)

    +0.0005 (+0.05%)
  • 10-Yr Bond

    +0.0570 (+3.75%)

    +0.0074 (+0.54%)

    +0.5230 (+0.46%)

    +1,061.82 (+1.77%)
  • CMC Crypto 200

    +57.32 (+4.07%)
  • FTSE 100

    +26.32 (+0.37%)
  • Nikkei 225

    +517.70 (+1.81%)

Alpine Immune Sciences Announces Executive Leadership Addition and Promotion

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Pamela Holland, Ph.D., Joins as Senior Vice President, Research

  • Remy Durand, Ph.D., Promoted to Chief Business Officer

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the appointment of Pamela Holland, Ph.D., as Senior Vice President, Research. Dr. Holland is an experienced cancer biologist with a proven track record of successfully discovering and progressing multiple pre-clinical therapeutics into clinical development.

"We are delighted to welcome Pam to the Alpine team," said Stanford Peng, MD, Ph.D., President and Head of Research and Development for Alpine. "Dr. Holland’s expertise with signal transduction and immunotherapies, particularly in cancer biology, will greatly assist our continued efforts to discover first- or best-in-class multifunctional immunotherapies, and to advance our existing programs into and through the clinic."

"I’m pleased to be joining Alpine Immune Sciences at such a meaningful time in the company’s history," said Dr. Holland. "Alpine is in a unique position and 2021 will be an exciting year for the company as we advance ALPN-101 with our partner AbbVie, gain further clinical experience with ALPN-202 in the NEON-1 study, and move ALPN-303, our dual APRIL/BAFF inhibitor for B cell mediated inflammatory diseases, into the clinic."

Most recently, Dr. Holland served as Vice President, Cancer Biology at Surface Oncology (NASDAQ: SURF), overseeing biology and immunology research. During her tenure she played key roles in developing the Surface pipeline, driving multiple pre-clinical programs into Phase 1, as well as the establishment of an early strategic partnership with Novartis and more recently with GSK. Prior to joining Surface, Dr. Holland held roles of increasing responsibility in oncology research at Amgen, working extensively on TNF-receptor superfamily members, including death-receptor agonists. Members of her team were instrumental in the development of multiple discovery programs for cancer immunotherapy. Dr. Holland received her bachelor’s degree from the University of California, San Diego and her doctorate degree in biochemistry from the University of Washington/Fred Hutchinson Cancer Research Center in the lab of Dr. Jonathan Cooper. Prior to entering graduate school, she worked at Cetus Corporation in Emeryville, California, where she was a key contributor to the development of TaqMan™. She is a co-inventor on all TaqMan patents and was the lead author on the first publication describing TaqMan in 1991.

Alpine Immune Sciences also announced that Remy Durand, Ph.D., currently Senior Vice President of Business Development and Corporate Strategy, has been promoted to Chief Business Officer. Dr. Durand joined Alpine Immune Sciences in 2018 to help lead the company’s corporate strategy and business development efforts. During his tenure, he has played a leading role in building the company’s partnerships with AbbVie and Adaptimmune, and has represented the company at investor meetings and conferences. Dr. Durand’s professional experience includes equity investing and strategy consulting in the life sciences. Prior to joining Alpine Immune Sciences, Dr. Durand was a Vice President on the life sciences investment team at Frazier Healthcare Partners, a leading provider of growth and venture capital to healthcare companies. Earlier in his career, Dr. Durand held roles of increasing responsibility at GE Ventures and L.E.K. Consulting, a premier strategic advisor to the life sciences industry. Dr. Durand received his Ph.D. in Bioengineering from Stanford University in the lab of Karl Deisseroth and was an NSF Graduate Research Fellow.

"Remy has demonstrated exceptional leadership in helping to drive the company’s corporate strategy, including our business development and investor relations activities," said Dr. Mitchell Gold, Chief Executive Officer of Alpine Immune Sciences. "I look forward to partnering with him, Pam, and the rest of the executive leadership team as we continue to advance our unique pipeline of immune therapeutics to improve patients’ lives."

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is creating first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

"Secreted Immunomodulatory Proteins," "SIP," "Transmembrane Immunomodulatory Protein," "TIP," "Variant Ig Domain," "vIgD" and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005296/en/


Paul Rickey
Chief Financial Officer
Alpine Immune Sciences, Inc.

Laurence Watts
Managing Director
Gilmartin Group, LLC.